Antidiabetic Agents Flashcards
Insulin lispro
Rapid-acting Insulin
Duration: 3-5 hours
Insulin aspart
Rapid-acting Insulin
Duration: 3-5 hours
Insulin glulisine
Rapid-acting Insulin
Duration: 3-5 hours
Inhaled insulin
Rapid-acting Insulin
Duration: 3-5 hours
Regular insulin
Short-acting insulin
Duration: 4-12 hours
NPH (neutral protamine hagedorn)
Intermediate-acting insulin
Duration: 10-20 hours
Glargine
Long-acting insulin
duration: 12-20 hours
causes stinging at injection site (acidic)
Detemir
Long-acting insulin
duration: 22-24 hours
Metformin
MOA: ↓ hepatic glucose output / ↑ peripheral glucose utilization
SE: GI / Vit. B12 deficiency
1st line agent
Glimepiride
Sulfonylurea
Rx: diabetes
MOA: inhibition of ATP-sensitive K channel of B cell -> insulin release
SE: ↑ weight, hypoglycemia
Glipizide
Sulfonylurea
Rx: diabetes
MOA: inhibition of ATP-sensitive K channel of B cell -> insulin release
SE: ↑ weight, hypoglycemia
Glyburide
Sulfonylurea
Rx: diabetes
MOA: inhibition of ATP-sensitive K channel of B cell -> insulin release
SE: ↑ weight, hypoglycemia
Repaglinide
Meglitinide
Rx: diabetes
MOA: inhibition of ATP-sensitive K channel of B cell -> insulin release
SE: ↑ weight, hypoglycemia
Nateglinide
Meglitinide
Rx: diabetes
MOA: inhibition of ATP-sensitive K channel of B cell -> insulin release
SE: ↑ weight, hypoglycemia
Acarbose
Glucosidase Inhibitor
Rx: diabetes
MOA: inhibition of brush border glucosidase enzyme -> ↓ glucose absorption
SE: abdominal pain, Diarrhea, flatulence
contraindicated w/ GI dz
Miglitol
Glucosidase Inhibitor
Rx: diabetes
MOA: inhibition of brush border glucosidase enzyme -> ↓ glucose absorption
SE: abdominal pain, Diarrhea, flatulence
contraindicated w/ GI dz
Pioglitzone
Thiazolidinedione
Rx: diabetes
MOA: activation of PPAR-gamma -> ↑ expression of GLUT4 channel
SE: CV, edema, ↑ weight, hypoglycemia
Rosiglitazone
Thiazolidinedione
Rx: diabetes
MOA: activation of PPAR-gamma -> ↑ expression of GLUT4 channel
SE: CV, edema, ↑ weight, hypoglycemia
pramlintide
amylinomimetic
Rx: diabetes
MOA: inhibit glucagon release / inhibit gastric emptying / anoretic effect
SE: N/V, anorexia, hypoglycemia
IV administration only
Exenatide
Incretin
Rx: diabetes
MOA: potentiate insulin secretion / inhibit glucagon release / inhibit gastric emptying / anoretic effect
SE: N/V/D, hypoglycemia, pancreatitis
Sitagliptin
dipeptidyl peptidase inhibitor
Rx: diabetes
MOA: inhibit incretin degradation
SE: nasopharyngitis / URI / HA / pancreatitis (acute, hemorrhagic, necrotizing)
oral administration